Joseph E Carroll

US Patent:

6953778, Oct 11, 2005

Filed:

Oct 28, 2002

Appl. No.:

10/281867

Inventors:

Joseph M. Carroll - Cambridge MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K038/00
G01N033/53
C07K014/00

US Classification:

514 12, 530350, 435 792

Abstract:

The present invention relates to methods and compositions for the diagnosis and treatment of hematological disorders, including, but not limited to, apalstic anemia, hemophilia, sickle cell anemia, thalassisemia, blood loss and other blood disorders, e. g. , blood diorders related to bone marrow irradiation or chemotherapy treatment or renal failure. The invention further provides methods for identifying a compound capable of treating a hematological disorder. The invention also provides methods for identifying a compound capable of modulating a hematopoietic cell activity. Yet further, the invention provides a method for modulating a hematopoietic cell activity. In addition, the invention provides a method for treating a subject having a hematological disorder characterized by aberrant 2777 polypeptide activity or aberrant 2777 nucleic acid expression. In another aspect, the invention provides methods for increasing hematopoietic cell proliferation in a subject and methods for modulating hematopoietic cell apoptosis in a subject.

US Patent:

7045505, May 16, 2006

Filed:

Sep 27, 2002

Appl. No.:

10/256537

Inventors:

Joseph M. Carroll - Cambridge MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 38/00

US Classification:

514 12

Abstract:

Isolated nucleic acids molecules, designated 69039 nucleic acid molecules, which encode novel Na/Ca exchanger members, are disclosed. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 69039 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 69039 gene has been introduced or disrupted. Isolated 69039 proteins, fusion proteins, antigenic peptides and anti-69039 antibodies are also disclosed. The invention further provides methods of treating, preventing and diagnosing hematopoietic and neurological disorders.

US Patent:

7094587, Aug 22, 2006

Filed:

Mar 18, 2003

Appl. No.:

10/391364

Inventors:

Rachel E. Meyers - Newton MA, US
Joseph M. Carroll - Cambridge MA, US
William James Cook - Hanover NH, US
Nadine S. Weich - Brookline MA, US
Rajasekhar Bandaru - Watertown MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C12N 9/12

US Classification:

435194, 536 232

Abstract:

The invention provides isolated nucleic acids molecules, designated 16002 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16002 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16002 gene has been introduced or disrupted. The invention still further provides isolated 16002 proteins, fusion proteins, antigenic peptides and anti-16002 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

US Patent:

7098015, Aug 29, 2006

Filed:

Mar 11, 2003

Appl. No.:

10/386414

Inventors:

Kyle J. MacBeth - Boston MA, US
Joseph M. Carroll - Cambridge MA, US
William James Cook - Hanover NH, US
Rachel E. Meyers - Newton MA, US
Miyoung Chun - Belmont CA, US
Mark J. Williamson - Saugus MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C12N 9/16
C12N 15/54
C12N 15/62
C12N 15/79

US Classification:

435196, 435 691, 435 697

Abstract:

The invention provides isolated nucleic acids molecules, designated 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27875, 22025, 27420, 16319, 55092 and 10218 gene has been introduced or disrupted. The invention still further provides isolated 27875, 22025, 27420, 17906, 16319, 55092 or 10218 proteins, fusion proteins, antigenic peptides and anti-27875, 22025, 27420, 17906, 16319, 55092 or 10218 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

US Patent:

7250262, Jul 31, 2007

Filed:

Jan 28, 2003

Appl. No.:

10/352684

Inventors:

Joseph M. Carroll - Cambridge MA, US
Aileen Healy - Medford MA, US
Nadine S. Weich - Brookline MA, US
Louise M. Kelly - Brookline MA, US

Assignee:

Bayerhealth Care AG - Leverkusen

International Classification:

G01N 33/53

US Classification:

435 71, 514 2, 514 12, 530350, 5303871, 530300

Abstract:

The present invention relates to methods for the diagnosis and treatment of hematological disorders. Specifically, the present invention identifies the differential expression of 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 and 13249 genes in tissues relating to hematological disorders sensation, relative to their expression in normal, or non-hematological disorders disease states, and/or in response to manipulations relevant to hematological disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hematological disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating hematological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of hematological disorders.

US Patent:

7351566, Apr 1, 2008

Filed:

May 5, 2006

Appl. No.:

11/429599

Inventors:

Rachel E. Meyers - Newton MA, US
Joseph M. Carroll - Cambridge MA, US
William James Cook - Hanover NH, US
Nadine S. Weich - Brookline MA, US
Rajasekhar Bandaru - Watertown MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C12N 9/12
C12N 5/00
C07H 21/04

US Classification:

435194, 4352523, 43525233, 435325, 4352541, 4353021, 536 232

Abstract:

The invention provides isolated nucleic acids molecules, designated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 gene has been introduced or disrupted. The invention still further provides isolated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 proteins, fusion proteins, antigenic peptides and anti-27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

US Patent:

7485308, Feb 3, 2009

Filed:

Jul 26, 2006

Appl. No.:

11/493347

Inventors:

Rachel E. Meyers - Newton MA, US
Kyle J. MacBeth - Boston MA, US
Rory A. J. Curtis - Ashland MA, US
Laura A. Rudolph-Owen - Medford MA, US
Nadine S. Weich - Brookline MA, US
Peter J. Olandt - Buffalo NY, US
Joseph M. Carroll - Cambridge MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 39/00
C12P 21/06

US Classification:

4241921, 435 691

Abstract:

The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 proteins, fusion proteins, antigenic peptides and anti-26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

US Patent:

20020076764, Jun 20, 2002

Filed:

Sep 10, 2001

Appl. No.:

09/950370

Inventors:

Rachel Meyers - Newton MA, US
Joseph Carroll - Cambridge MA, US

Assignee:

Millennium pharmaceuticals, Inc. - Cambridge MA

International Classification:

C12N009/16
C07H021/04
C12P021/02
C12N005/06

US Classification:

435/069100, 435/196000, 435/325000, 435/320100, 536/023200

Abstract:

The invention provides isolated nucleic acids molecules, designated 27877 nucleic acid molecules, which encode a novel phospholipase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 27877 gene has been introduced or disrupted. The invention still further provides isolated 27877 proteins, fusion proteins, antigenic peptides and anti-27877 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.